A month after conducting significant layoffs, Biofourmis is out a CEO: Kuldeep Singh Rajput, one of the company’s founders, has quietly stepped down from his role.
A Biofourmis spokesperson confirmed Rajput’s departure to STAT on Wednesday, and said that while the company hunts for a new CEO it will be helmed by a committee of executives overseen by new board member Ben Wanamaker, a partner at Biofourmis investor General Atlantic. The Boston-based company was valued at $1.3 billion following a $320 million Series D financing round which closed last summer and brought big names to Biofourmis: CVS Health was an investor, and Omar Ishrak, former CEO of Medtronic, and Sachin Jain, CEO of the SCAN Health Plan joined the board.
Founded in 2015, Biofourmis has been developing a dizzying array of tech-enabled care offerings, including home-based care services for hospitals, clinical trials support for biopharma companies, and a pipeline of software-based interventions for heart failure and other conditions.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect